Affiliation: University of British Columbia
- Biomarkers in newly diagnosed pediatric-extensive chronic graft-versus-host disease: a report from the Children's Oncology GroupHisaki Fujii
Children s Oncology Group, Division of Hematology Oncology Bone Marrow Transplantation, Department of Pediatrics, BC Children s Hospital University of British Columbia, Vancouver, BC, Canada
Blood 111:3276-85. 2008..This study is registered at www.cancer.gov/clinicaltrials as no. COG-ASCT0031...
- Philadelphia chromosome-positive acute lymphoblastic leukemia in children: new and emerging treatment optionsKirk R Schultz
Division of Pedatric Hematology, Oncology, Blood and Marrow Transplantation, British Columbia Children s Hospital, University of British Columbia, Vancouver, BC, Canada
Expert Rev Hematol 3:731-42. 2010..The experience of adding a targeted agent such as a TKI to the standard chemotherapy regimen suggests that this strategy might be applied to other ALL subtypes to achieve both increased efficacy and decreased toxicity...
- Anti-CD13 Abs in children with extensive chronic GVHD and their relation to soluble CD13 after allogeneic blood and marrow transplantation from a Children's Oncology Groups Study, ASCT0031G D E Cuvelier
Manitoba Blood and Marrow Transplantation Program, CancerCare Manitoba, University of Manitoba, Winnipeg, Manitoba, Canada
Bone Marrow Transplant 45:1653-7. 2010..These data do not confirm that induction of CD13 reactive Abs is a mechanism for cGVHD in children nor are part of the pathogenesis of cGVHD associated with elevated soluble CD13. The exact role of CD13 in cGVHD remains to be determined...
- Toward biomarkers for chronic graft-versus-host disease: National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: III. Biomarker Working Group ReportKirk R Schultz
British Columbia Children s Hospital, University of British Columbia, Vancouver, British Columbia, Canada
Biol Blood Marrow Transplant 12:126-37. 2006..Both approaches have merit and should be pursued. The consistent treatment and standardized documentation needed to support biomarker studies are most likely to be satisfied in prospective clinical trials...
- Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children's oncology group studyKirk R Schultz
Department of Pediatrics, Division of Hematology Oncology Bone Marrow Transplantation, University of British Columbia, B C s Children s Hospital, Vancouver, BC, V6H 3V4, Canada
J Clin Oncol 27:5175-81. 2009..Imatinib mesylate is a targeted agent that may be used against Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL), one of the highest risk pediatric ALL groups...
- Chloroquine prevention of murine MHC-disparate acute graft-versus-host disease correlates with inhibition of splenic response to CpG oligodeoxynucleotides and alterations in T-cell cytokine productionKirk R Schultz
Department of Pediatrics, Division of Hematology Oncology Bone Marrow Transplantation, University of British Columbia and British Columbia s Children s Hospital, Vancouver, British Columbia, Canada
Biol Blood Marrow Transplant 8:648-55. 2002..Other mechanisms involved may include suppression of CD8+ T-cell production of IL-2 and IL-4 and an increase in NKT cells associated with GVHD inhibition by chloroquine...
- Risk- and response-based classification of childhood B-precursor acute lymphoblastic leukemia: a combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children's Cancer Group (CCG)Kirk R Schultz
Children s Oncology Group, Department of Pediatrics, BC Children s Hospital, University of British Columbia, Vancouver, Canada
Blood 109:926-35. 2007....
- CpG stimulation of precursor B-lineage acute lymphoblastic leukemia induces a distinct change in costimulatory molecule expression and shifts allogeneic T cells toward a Th1 responseGregor S D Reid
Room 217, BCRI, 950 W 28th Ave, Vancouver, BC V5Z 4H4, Canada
Blood 105:3641-7. 2005..These results demonstrate the functional relevance of CpG stimulation of precursor B-ALL cells and provide a rational basis for study of these agents for use in treatment of this disease...
- Altered Toll-like receptor 9 responses in circulating B cells at the onset of extensive chronic graft-versus-host diseaseKevin She
Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada
Biol Blood Marrow Transplant 13:386-97. 2007..07). These findings suggest that an increased number of B cells, primed for a TLR9 response, may play a role in the pathophysiology of cGVHD...
- Altered patterns of T cell cytokine production induced by relapsed pre-B ALL cellsGregor S D Reid
Department of Pediatrics, University of British Columbia and B C s Children s Hospital, 4480 Oak Street, BC V5Z 4H4 Vancouver, Canada
Leuk Res 27:1135-42. 2003....
- Acute T-cell leukemias remain dependent on Notch signaling despite PTEN and INK4A/ARF lossHind Medyouf
Terry Fox Laboratory, BC Cancer Agency, Vancouver, BC
Blood 115:1175-84. 2010..Thus, in contrast to previous findings with established cell lines, these results indicate PTEN loss does not relieve primary T-ALL cells of their "addiction" to Notch signaling...
- A phase II study of imatinib mesylate in children with refractory or relapsed solid tumors: a Children's Oncology Group studyMason Bond
B C Children s Hospital, Vancouver, British Columbia, Canada
Pediatr Blood Cancer 50:254-8. 2008..A phase II study of imatinib in children and young adults with select solid tumors was performed...
- In vivo control of acute lymphoblastic leukemia by immunostimulatory CpG oligonucleotidesHisaki Fujii
Department of Pediatrics, Division of Hematology Oncology Bone Marrow Transplantation, University of British Columbia and British Columbia s Children s Hospital, Vancouver, Canada
Blood 109:2008-13. 2007..These results suggest that CpG ODNs have potential as therapeutic agents for the treatment of ALL...
- ETV6 (TEL)-AML1 pre-B acute lymphoblastic leukaemia cells are associated with a distinct antigen-presenting phenotypeAngela J Alessandri
Department of Pediatrics, Division of Hematology Oncology Bone Marrow Transplantation, University of British Columbia and British Columbia s Children s Hospital, Vancouver, BC, Canada
Br J Haematol 116:266-72. 2002..In the case of ETV6-AML1 pre-B ALL, this characteristic immunophenotype may have implications for the immunogenicity of the leukaemic cells...
- A population-based study of pediatric anaplastic large cell lymphomaAngela J Alessandri
Department of Paediatrics, Division of Hematology Oncology Bone Marrow Transplantation, British Columbia s Children s Hospital, Vancouver, British Columbia, Canada
Cancer 94:1830-5. 2002..To the authors' knowledge, there are no population-based pediatric studies in the literature, and incidence estimates have not been attempted...
- Measuring therapeutic response in chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. Response Criteria Working Group reportSteven Z Pavletic
National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892 1203, USA
Biol Blood Marrow Transplant 12:252-66. 2006..The proposed response criteria are based on current expert consensus opinion and are intended to improve consistency in the conduct and reporting of chronic GVHD trials, but their use remains to be demonstrated in practice...
- National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: VI. Design of Clinical Trials Working Group reportPaul J Martin
Fred Hutchinson Cancer Research Center, University of Washington School of Medicine, Seattle, Washington 98109 1024, USA, and Hopital St Louis, Paris, France
Biol Blood Marrow Transplant 12:491-505. 2006..The use of consistent standards in clinical trial designs to evaluate agents that have activity in pathogenic pathways could facilitate advances in the treatment of chronic GVHD...
- Autologous versus allogeneic unrelated donor transplantation for acute lymphoblastic leukemia: comparative toxicity and outcomesDaniel Weisdorf
University of Minnesota, the National Marrow Donor Program and the Autologous Blood and Marrow Transplant Registry, Minneapolis 55455, USA
Biol Blood Marrow Transplant 8:213-20. 2002....
- Comparison of outcome following allogeneic bone marrow transplantation with cyclophosphamide-total body irradiation versus busulphan-cyclophosphamide conditioning regimens for acute myelogenous leukaemia in first remissionMark R Litzow
Mayo Clinic and Foundation, Rochester, MN, USA
Br J Haematol 119:1115-24. 2002..016). There were no differences in TRM, LFS and OS. CyTBI conditioning may lower relapse risk but produces comparable TRM, LFS and OS to BuCy for HLA-matched sibling transplantation in first remission AML...
- Chronic Graft-versus-Host Disease--implementation of the National Institutes of Health Consensus Criteria for Clinical TrialsLinda M Griffith
Division of Allergy, Immunology and Transplantation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA
Biol Blood Marrow Transplant 14:379-84. 2008
- Detection of WT1-specific T cells in paediatric acute lymphoblastic leukaemia patients in first remissionDraga Barbaric
Br J Haematol 141:271-3. 2008
- Non-resectable congenital tumors with the ETV6-NTRK3 gene fusion are highly responsive to chemotherapyEmma McCahon
Oncology Department, The Children s Hospital Westmead, New South Wales, Australia
Med Pediatr Oncol 40:288-92. 2003..For both these tumors standard curative treatment has been primarily surgical with wide local excision. This has frequently involved radical and even mutilating surgery...
- A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcomeCorey S Cutler
International Bone Marrow Transplant Registry, Medical College of Wisconsin, 8701 Watertown Plank Rd, PO Box 26509, Milwaukee, WI 53226, USA
Blood 104:579-85. 2004..For low- and intermediate-1-risk MDS, delayed BMT is associated with maximal life expectancy, whereas immediate transplantation for intermediate-2- and high-risk disease is associated with maximal life expectancy...
- Canadian multicenter pilot trial of haploidentical donor transplantationIrwin Walker
McMaster University, Hamilton, Ontario, Canada
Blood Cells Mol Dis 33:222-6. 2004..Canadian multicenter pilot study of haploidentical donor...
- Allogeneic bone marrow transplantation in first remission for children with ultra-high-risk features of acute lymphoblastic leukemia: A children's oncology group study reportPrakash Satwani
Morgan Stanley Children s Hospital of NewYork Presbyterian, Columbia University, New York, New York 10032, USA
Biol Blood Marrow Transplant 13:218-27. 2007..Randomized prospective cooperative group studies are required to establish the role of allogeneic hematopoietic stem cell transplantation versus intensive chemotherapy in children with UHRF ALL in CR1...
- Outcome of ethnic minorities with acute or chronic leukemia treated with hematopoietic stem-cell transplantation in the United StatesK Scott Baker
Pediatric Blood and Marrow Transplant Program, University of Minnesota, Mayo Mail Code 484, Minneapolis, MN 55455, USA
J Clin Oncol 23:7032-42. 2005..The purpose of this study was to examine the relationship between ethnicity and post-transplantation events and determine their net effect on survival...
- Cardiac manifestations of graft-versus-host diseaseCynthia Rackley
Department of Pediatrics, Children s Memorial Hospital, Chicago, Illinois, USA
Biol Blood Marrow Transplant 11:773-80. 2005..Although they are uncommon, it is important to recognize these cardiac manifestations, because they may reflect GVHD activity and may be reversible by increasing immunosuppression...
- A comparison of cyclophosphamide and total body irradiation with etoposide and total body irradiation as conditioning regimens for patients undergoing sibling allografting for acute lymphoblastic leukemia in first or second complete remissionDavid I Marks
Adult BMT Unit, Bristol Children s Hospital, Bristol, UK
Biol Blood Marrow Transplant 12:438-53. 2006..We conclude that for HLA-identical sibling allografts for acute lymphoblastic leukemia in CR2, there is an advantage in substituting etoposide for Cy or, when Cy is used, in increasing the TBI dose to > or =13 Gy...
- Use of G-CSF in matched sibling donor pediatric allogeneic transplantation: a consensus statement from the Children's Oncology Group (COG) Transplant Discipline Committee and Pediatric Blood and Marrow Transplant Consortium (PBMTC) Executive CommitteeStephan A Grupp
Children s Hospital of Philadelphia, Philadelphia, Pennsylvania 19104, USA
Pediatr Blood Cancer 46:414-21. 2006..We conclude that the approach is promising and warrants further study. Risks of G-CSF to the donor are minimal and benefits to both donor and recipient may occur...
- Transplantation of G-CSF Stimulated Marrow vs BloodKirk Schultz; Fiscal Year: 2006..The immunological studies will be used to develop innovative strategies to improve patient outcomes with graft engineering of G-PB. This study will have a worldwide impact on how BMT is performed in the future. ..
- Transplantation of G-CSF Stimulated Marrow vs BloodKirk Schultz; Fiscal Year: 2007..The immunological studies will be used to develop innovative strategies to improve patient outcomes with graft engineering of G-PB. This study will have a worldwide impact on how BMT is performed in the future. ..
- Blood and Marrow Transplant Clinical Trials NetworkKirk Schultz; Fiscal Year: 2007..End of abstract.) ..
- Transplantation of G-CSF Stimulated Marrow vs BloodKirk Schultz; Fiscal Year: 2009..The immunological studies will be used to develop innovative strategies to improve patient outcomes with graft engineering of G-PB. This study will have a worldwide impact on how BMT is performed in the future. ..
- Transplantation of G-CSF Stimulated Marrow vs BloodKirk R Schultz; Fiscal Year: 2010